Loader

Pathways

PathWhiz ID Pathway Meta Data

PW145427

Pw145427 View Pathway
drug action

Aminophenazone Drug Metabolism Action Pathway

Homo sapiens

PW175966

Pw175966 View Pathway
metabolic

Aminohippuric acid Predicted Metabolism Pathway new

Homo sapiens
Metabolites of Aminohippuric acid are predicted with biotransformer.

PW144483

Pw144483 View Pathway
drug action

Aminoglutethimide Drug Metabolism Action Pathway

Homo sapiens

PW144632

Pw144632 View Pathway
drug action

Aminocaproic acid Drug Metabolism Action Pathway

Homo sapiens

PW124120

Pw124120 View Pathway
drug action

Aminocaproic Acid Drug Action Action Pathway (New)

Homo sapiens
Aminocaproic acid (also known as ε-aminocaproic acid, ε-Ahx, or 6-aminohexanoic acid; brand name Amicar) is a derivative of lysine, meaning that it acts as an amino acid analogue and can alter functionality of enzymes that require lysine residue binding (e.g. amino acid transporters such as the SLC3A2/SLC7A6 proteins, fibrin, tissue-type plasminogen activator, apolipoprotein(a), aldehyde oxidase, etc.). After oral or intravenous administration, it reaches the bloodstream and can act at the site of vascular injury (or other cause of excess bleeding) where the coagulation (i.e. blood clotting) takes place. Aminocaproic acid is an antifibrinolytic drug. Antifibrinolytics drugs are commonly used during major surgery to prevent significant blood loss (e.g. a liver transplant). By reversibly blocking the binding sites on plasminogen, aminocaproic acid creates a ‘blockade’ in the process of fibrinolysis - this blockade inhibits plasminogen binding to fibrin and the conversion of plasminogen to plasmin (a proteolytic enzyme), preventing fibrin degradation to maintain the stability of fibrin mesh/clots formed through the coagulation cascade. Thus, it reduces clot breakdown and can treat acute bleeding due to elevated fibrinolysis. An orphan drug FDA-approved to prevent recurring hemorrhage in certain patients, aminocaproic acid is also used off-label to control bleeding in patients with immune or nonimmune severe thrombocytopenia (bleeding disorder due to low platelet count). Unlike many other antifibrinolytics, it has no serious side effects at therapeutic doses and there is no evidence that suggests an increased risk of thrombosis.

PW000308

Pw000308 View Pathway
drug action

Aminocaproic Acid Action Pathway

Homo sapiens
Aminocaproic acid, brand name Amicar, is a derivate of lysine and is an antifibrinolytic drug. Antifibrinolytics drugs are commonly used during major surgery to prevent significant blood loss. These drugs reversibly blocks the binding sites on plasminogen. This blockade inhibits plasminogen binding to fibrin and the conversion of plasminogen to plasmin. These prevents fibrin degradation and maintains the stability of fibrin clots.

PW176447

Pw176447 View Pathway
metabolic

Aminobenzoic acid Predicted Metabolism Pathway

Homo sapiens
Metabolites of Template4MB1 are predicted with biotransformer.

PW064551

Pw064551 View Pathway
metabolic

Amino Sugar Metabolism

Mus musculus
Amino sugars are sugar molecules containing an amine group. They make up many polysaccharides including, glycosaminoglycans or mucopolysaccharides.

PW088194

Pw088194 View Pathway
metabolic

Amino Sugar Metabolism

Bos taurus
Amino sugars are sugar molecules containing an amine group. They make up many polysaccharides including, glycosaminoglycans or mucopolysaccharides.

PW088300

Pw088300 View Pathway
metabolic

Amino Sugar Metabolism

Rattus norvegicus
Amino sugars are sugar molecules containing an amine group. They make up many polysaccharides including, glycosaminoglycans or mucopolysaccharides.